Bridgewater, New Jersey, September 6, 2016 – Amneal Pharmaceuticals LLC today announced the appointment of Sheldon Hirt as senior vice president and general counsel, effective September 13, 2016. Mr. Hirt will succeed Robert Loewenstein, who has served in the role since 2011 and will be retiring.
Mr. Hirt brings more than 20 years of experience as a corporate lawyer. Most recently, he was the executive vice president and general counsel for Progenics Pharmaceuticals, overseeing all legal and compliance matters for the company. Previous to Progenics, he was senior vice president and assistant general counsel at Allergan where he worked on major acquisitions, licensing and development collaborations, and strategic investments, such as the acquisitions/integration of Actavis, Forest Laboratories, and Warner Chilcott. He also held various leadership positions at Barr Laboratories and Johnson & Johnson, and spent several years in private law practice. Mr. Hirt was also an infantry officer in the United States Marine Corps.
“Sheldon’s in-depth knowledge of the pharmaceutical industry and the increasing importance of generic medicines make him well-suited to lead our legal and compliance affairs,” said Chirag Patel, co-CEO and chairman of Amneal Pharmaceuticals. “I am confident under Sheldon’s leadership, we will continue to build on the successes we have achieved to bring high quality and affordable medicines to market.”
Mr. Hirt received his bachelor’s degree from Columbia College in New York, and his master’s degree from Columbia University School of International and Public Affairs. He completed his juris doctor degree at Columbia Law School. Mr. Hirt is a board member of Ei3 Corporation, a New Jersey-based software provider.
Amneal Pharmaceuticals, a member of The Amneal Alliance of companies, is the fastest growing generics pharmaceutical manufacturer in the world. Founded in 2002, it is a privately-held company headquartered in Bridgewater, New Jersey and has now more than 4,000 employees in its operations in North America, Asia, Australia and Europe, working together to bring high quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.